343269-52-3

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2-hydroxy-3-methylaniline is used as an intermediate in the synthesis of various pharmaceuticals for its unique reactivity and properties that contribute to the development of new drugs.
Used in Dye Industry:
5-Bromo-2-hydroxy-3-methylaniline is used as an intermediate in the synthesis of dyes due to its ability to contribute to the color and stability of the dyes produced.
Used in Specialty Chemicals Synthesis:
5-Bromo-2-hydroxy-3-methylaniline is used as a starting material for the synthesis of specialty chemicals, taking advantage of its unique structure and reactivity to create compounds with specific applications.
Used in Advanced Materials Development:
5-Bromo-2-hydroxy-3-methylaniline is used as a starting material for the development of advanced materials, leveraging its properties to contribute to the creation of innovative and high-performance materials in various industries.

Upstream product

• 2362-12-1 4-Bromo-2-methylphenol 
• 20294-50-2 4-bromo-2-methyl-6-nitrophenol 

Downstream Products

• 1300745-37-2 C₁₄H₁₁BrN₂O₄ 
• 942215-50-1 2-(4-aminophenyl)-7-methyl-1,3-benzoxazole-5-carbonitrile 
• 942215-52-3 4-(5-bromo-7-methyl-1,3-benzoxazol-2-yl)aniline 
• 942215-51-2 5-bromo-7-methyl-2-(4-nitrophenyl)-1,3-benzoxazole 
• 1268599-73-0 C₂₈H₂₅N₅O₄ 
• 1268599-72-9 C₃₀H₂₉N₅O₄ 
• 1268599-71-8 C₂₈H₂₅N₅O₄ 
• 1268599-70-7 C₂₉H₂₇N₅O₄ 
• 942214-09-7 C₂₇H₂₄ClN₅O₂ 
• 942214-12-2 C₂₈H₂₇N₅O₃ 
• 942214-11-1 C₂₈H₂₇N₅O₃ 
• 942211-78-1 C₂₇H₃₀N₄O₄ 
• 942211-77-0 C₂₈H₃₂N₄O₄ 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS AND METHODS OF USE

The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS

Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

SUBSTITUTED NITROGEN CONTAINING COMPOUNDS

Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

Novel benzoxazolone compound

PROBLEM TO BE SOLVED: To provide a therapeutic agent for diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small diameter fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria or multiple sclerosis. SOLUTION: There is provided a benzoxazolone compound represented by the formula (1) or a pharmaceutically acceptable salt. (1), where R1 and R2 are each independently H or C1-6 alkyl, where the alkyl may be substituted by hydroxy, C1-4 alkylsulfonyl, aminocarbonyl or 4 to 7-membered heterocycloalkyl, or the like, L is C1-6 alkylene, R3 is C1-6 alkyl, C3-7 cycloalkyl, where the cycloalkyl may be substituted by halogen or hydroxy or the like, C6-10 aryl, where the aryl may be substituted by halogen, C1-4 alkyl or C1-4 haloalkyl or the like, R4 is H, halogen or C1-4 alkyl. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

NOVEL PDE4 INHIBITOR

Provided is a compound represented by formula (1a) or a pharmacologically acceptable salt thereof However, R 1 to R 6 in the formula each independently represent an alkyl group or the like.

2-Arylbenzoxazoles as CETP inhibitors: Raising HDL-C in cynoCETP transgenic mice

We describe structure-activity studies leading to the discovery of 2-arylbenzoxazole 3, the first in a series to raise serum high-density lipoprotein cholesterol levels in transgenic mice. Replacement of the 4-piperidinyloxy moiety with piperazinyl provid

CETP INHIBITORS

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I